ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluconazole

Also written as “fluconazole”, “Fluconazole 400 mg” and “Diflucan®”.

Its studies are mostly in Meningitis, Cryptococcal · Candidiasis · Candidiasis, Oral · Candidemia · Lymphoma, led by 8 companies.

Drug pageFluconazole: every studyMany companies study it; this page follows only the 37 they lead. All 104 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Nov 2, 199937 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only260 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Merck30 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
AstraZenecaits history only20 open or runningphase 1since Mar 20, 2014Mar 20, 2014none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Jan 13, 2012Jan 13, 2012none ahead
Bayerits history only10 open or runningphase 1since Apr 17, 2019Apr 17, 2019none ahead
Johnson & Johnsonits history only10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Pharmtechnologyits history only10 open or runningphase 1since Jul 26, 2019Jul 26, 2019none ahead
Sutphin Drugsits history only10 open or runningearly phase 1since Jul 31, 2020Jul 31, 2020none ahead

Also a collaborator on its studies: Altasciences, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene and Vicuron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First study: phase 3 study in Candidiasis, OralFirst studyNCT00002446 · 300 enrolled · United States, Barbados
  2. Nov 2, 1999Phase 2 study in Candidiasis, OralNCT00002399 · 500 enrolled · United States, Argentina, Belgium and more
  3. Dec 18, 2008Phase 3 study in LeukopeniaNCT00811928 · 252 enrolled

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule

Studies

All 3 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00811928Leukopenia3CompletedMay 2010252
NCT00002446Candidiasis, Oral · United States, Barbados3Completed300
NCT00002399Candidiasis, Oral · United States, Argentina, Belgium and more2Completed500

How it is read

Names in the registry

  • “Fluconazole”, 36 entries
  • “fluconazole”, 5 entries
  • “Fluconazole 400 mg”, 1 entry
  • “Diflucan®”, 1 entry
  • “Fluconazole 150mg Capsule Localized Originator”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.